LB Pharmaceuticals IncLBRX
Price$37.28

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Dec 2025
Net Income -$39MTTM through 31 Dec 2025
Free Cash Flow -$35.3MTTM through 31 Dec 2025

Margins

Current

Returns

-8.4%ROE
-8.1%ROA

Balance Sheet Health

Debt / Equity0.01x
Net Debt-$362.1Mnet cash position
Cash & Equivalents$295.2M

Quality Metrics

Earnings-Beat Rate0.0%

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Neuropsychiatric Drug Development$0
View details

Pivotal Phase 3 NOVA-2 trial in schizophrenia initiated in early 2026 with topline results expected in H2 2027.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.